SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.
SynZeal will update these details as per new development or finding in product specification without further noticed.
Nome Químico: (1R,3r,5R,7S)-3-((S)-1-((Tert-butoxycarbonyl)amino)-2-((1S,3S,5S)-3-cyano-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)adamantan-1-yl 2,2,2-trifluoroacetate
Shipping Temperature: Ambient
HSN Code: 38229010
Country of Origin: India
Sorrisos: O=C(O[C@@]12C[C@]3([C@H](NC(OC(C)(C)C)=O)C(N4[C@@]5([H])C[C@@]5([H])C[C@H]4C#N)=O)C[C@@](C2)([H])C[C@](C3)([H])C1)C(F)(F)F
Saxagliptin Impurity 52 is chemically (1R,3r,5R,7S)-3-((S)-1-((Tert-butoxycarbonyl)amino)-2-((1S,3S,5S)-3-cyano-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)adamantan-1-yl 2,2,2-trifluoroacetate. Saxagliptin Impurity 52 is supplied with detailed characterization data compliant with regulatory guideline. Saxagliptin Impurity 52 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Saxagliptin.
The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.
Development and validation of RP-HPLC method for simultaneous estimation of saxagliptin and dapagliflozin
By Desai, Charmy P.; Chaudhary, Ankit B.; Patel, Bhoomi D.
From World Journal of Pharmacy and Pharmaceutical Sciences (2018), 7(5), 803-812
Gradient elution RP-HPLC method for the determination of related substances in saxagliptin
By Li, Xiaoyan; Liu, Fei
From Zhongguo Yaopin Biaozhun (2015), 16(1), 16-19
Development and validation of simple stability indicating RP-HPLC method for analysis of saxagliptin and its forced degradation impurities in bulk drug and pharmaceutical dosage form
By Chhabda, Pawanjeet J.; Balaji, M.; Srinivasarao, V.; Ramakrishna, K.; Apparao, K. M. Ch.
From International Journal of Research and Development in Pharmacy & Life Sciences (2014), 3(3), 993-1003, 11 pp..